Effect of Sacubitril-Valsartan Combined with Zhenyuan Capsule in the Treatment of Chronic Heart Failure Comorbid Anxiety and Depression and Its Effect on Inflammatory Factors

Objective: To investigate the effect of sacubitril-valsartan combined with Zhenyuan capsule in treatment chronic heart failure comorbid anxiety and depression its on level inflammatory factors. Methods: A total 106 patients from February 2020 to March 2022 were continuously enrolled divided into control group (36 cases), observation cases) B (34 according methods. All groups given conventional treatment. On basis routine treatment, group, valsartan, plus Capsules for consecutive 8 weeks. The 3 evaluated by Self-rating Anxiety Scale (SAS) Depression (SDS) before after clinical efficacy was evaluated, detection left ventricular ejection fraction (LVEF), end systolic diameter (LVESD), end-diastolic (LVEDD), N terminal brain natriuretic peptide (NT-proBNP), tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), c-reactive protein (CRP) conducted. Results: rate effective significantly higher than those (P < 0.05), 0.05); SAS SDS scores lower LVEF three all increased compared levels LVESD, LVEDD, NT-proBNP, TNF-α, IL-6, hs-CRP decreased treatment; changes above indexes more significant 0.05). Except LVEDD index, had Conclusion: Sacubitril valsartan can improve cardiac function, reduce response, failure, combination Capsule is significant.